Close

CSL Seqirus is Fully Prepared to Implement the FDA's Vaccines and Related Biological Products Advisory Committee Trivalent Influenza Vaccines Strain Selection for the 2024/25 U.S. Season Mar 6, 2024 09:00AM
CSL Announces Top-line Results from the Phase 3 AEGIS-II Trial Evaluating the Efficacy and Safety of CSL112 (apolipoprotein A-I [human]) Feb 11, 2024 05:47PM
New COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine Booster Feb 5, 2024 08:30AM
Harris Poll Survey Finds People Receiving Treatment for CIDP Are Interested in Exploring More Convenient Treatment Options Jan 16, 2024 08:00AM
CSL Behring Announces Availability of Hizentra® (Immune Globulin Subcutaneous [Human] 20% Liquid) 10g Prefilled Syringe Jan 3, 2024 08:00AM
View Older Stories

Jan 2, 2024 08:00AM CSL Behring Demonstrates Continued Commitment to Alpha-1 Community with Addition of ZEMAIRA® [Alpha1-Proteinase Inhibitor (Human)] 4- and 5-Gram Vials
Dec 21, 2023 08:00AM CSL and Arcturus Therapeutics’ ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster
Dec 21, 2023 08:00AM CSL and Arcturus Therapeutics' ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster
Dec 14, 2023 02:47PM CSL's Garadacimab, a First-in-Class Factor XIIa Inhibitor, Receives FDA and EMA Filing Acceptance
Dec 11, 2023 07:30PM CSL Behring's HEMGENIX® (etranacogene dezaparvovec-drlb) Demonstrates at Three Years Post-Treatment Long-Term Durability, Safety and Greater Bleed Protection Versus Prophylactic Treatment in People L
Nov 28, 2023 08:06AM Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics' (ARCT) ARCT-154, the first Self-Amplifying mRNA vaccine approved for COVID in adults
Nov 28, 2023 08:05AM Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics' ARCT-154, the first Self-Amplifying mRNA vaccine approved for COVID in adults
Nov 28, 2023 08:00AM Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics’ ARCT-154, the First Self-Amplifying mRNA Vaccine Approved for COVID in Adults
Nov 24, 2023 02:00AM Iron Deficiency Day 2023: CSL Vifor calls for access to iron deficiency diagnosis and treatment
Oct 27, 2023 10:00AM CSL and uniQure Win 2023 Prix Galien USA Award
Oct 11, 2023 08:30AM New Data Presented at IDWeek 2023 Demonstrates Public Health Benefit and Cost Savings Associated with Cell-Based and Adjuvanted Influenza Vaccines
Sep 19, 2023 04:50AM CSL Seqirus Presents Real-World Evidence at ESWI Demonstrating the Impact of Influenza Vaccination Campaigns to Help Protect People and Healthcare Systems
Sep 5, 2023 08:30AM Arcturus Therapeutics and CSL Announce European Medicines Agency Validates Marketing Authorization Application for ARCT-154 Vaccine to Prevent COVID-19
Aug 28, 2023 08:30AM CSL Seqirus Announces Third U.S. Government Award in Relation to Influenza A(H5N8) Candidate Vaccine
Aug 17, 2023 07:08AM CSL Appoints Jeffrey Ball as First Chief Sustainability Officer
Jul 17, 2023 08:30AM CSL Seqirus Begins Shipping Portfolio of Innovative Influenza Vaccines for the 2023/24 U.S. Season
Jun 20, 2023 07:00AM CSL Behring Announces the First Patient Has Received FDA-Approved HEMGENIX® (etranacogene dezaparvovec-drlb) for Hemophilia B
May 18, 2023 02:00AM Kapruvia® (difelikefalin) recommended by England's NICE for the treatment of adults with moderate-to-severe CKD-associated pruritus
Apr 18, 2023 09:00AM CSL Behring Receives FDA Approval for Hizentra® (Immune Globulin Subcutaneous [Human] 20% Liquid) 50mL Prefilled Syringe
Mar 27, 2023 03:30PM CSL Opens New, State-of-the-Art Vaccine Research and Development Facility in Waltham, Massachusetts
Mar 1, 2023 08:00AM The Lancet Publishes Pivotal Phase 3 Data on CSL's First-in-Class Garadacimab for HAE
Feb 28, 2023 08:00AM Amarin and CSL Seqirus Announce Exclusive License and Distribution Agreement to Commercialize VAZKEPA® (Icosapent Ethyl) in Australia and New Zealand
Feb 26, 2023 10:45AM CSL's Phase 3 Study Shows First-In-Class Garadacimab Provides Patients with Significant HAE Attack Prevention with Monthly Dosing
Feb 23, 2023 08:00AM CSL's HOPE-B Data Published in the New England Journal of Medicine, Demonstrating Efficacy and Durability of HEMGENIX® (etranacogene dezaparvovec-drlb)
Feb 21, 2023 08:00AM Biotech Leader CSL Again Named Among America's Best Employers by Forbes
Feb 20, 2023 04:42PM First Gene Therapy for Hemophilia B, CSL's HEMGENIX®, Approved by the European Commission
Jan 10, 2023 08:00AM Ten Emerging Rare Disease Scientists Score Research Grants Totaling $200,000 From Uplifting Athletes
Jan 5, 2023 08:00AM SAB Biotherapeutics Novel DiversitAb™ Platform Proven to Develop Anti-idiotype Antibodies to Help Treat Autoimmune Diseases
Dec 12, 2022 05:46PM CSL Announces Next CEO & Managing Director
Dec 12, 2022 08:30AM CSL Announces Closing of Global Collaboration and Licensing Agreement with Arcturus Therapeutics
Dec 10, 2022 10:00AM CSL's Novel Gene Therapy HEMGENIX® (etranacogene dezaparvovec-drlb) Demonstrates Durable Protection and Sustained Factor IX Activity Levels for People Living with Hemophilia B at 24-Months Post-Treat
Nov 22, 2022 03:59PM U.S. Food and Drug Administration approves CSL's HEMGENIX® (etranacogene dezaparvovec-drlb), the first gene therapy for hemophilia B
Nov 2, 2022 06:30PM Next-Generation mRNA, Gene Therapy, Plasma Products, Monoclonal Antibodies, and Recent Acquisitions and Collaborations Highlight CSL R&D Day 2022
Nov 2, 2022 07:17AM Arcturus Therapeutics (ARCT) Announces Collaboration with CSL to Develop and Commercialize Self-amplifying mRNA Vaccines
Nov 1, 2022 06:05PM Arcturus Announces Collaboration with CSL to Develop and Commercialize Self-amplifying mRNA Vaccines
Nov 1, 2022 06:00PM CSL Enters Licensing Agreement with Arcturus Therapeutics for Next Generation mRNA Vaccine Technology
Oct 6, 2022 12:00PM CSL Seqirus Announces U.S. Government Award to Manufacture and Clinically Assess Influenza A(H5N8) Pre-Pandemic Vaccine
Oct 5, 2022 08:30AM CSL Announces Positive Preclinical Data for Self-Amplifying Messenger RNA (sa-mRNA) Influenza Vaccine Candidates
Sep 26, 2022 08:00AM New Data at OPTIONS XI Conference Highlight Burden of Seasonal Influenza on Health Systems and the Need for Increased Vaccination Rates
Sep 26, 2022 08:00AM New Real-World Data Presented at OPTIONS XI Show Cell-Based and MF59®-Adjuvanted Influenza Vaccines Can Reduce the Burden of Seasonal Influenza on Hospitals and Health Systems
Sep 13, 2022 10:00AM CSL presents new research and development center in Marburg, Germany
Sep 13, 2022 08:00AM CSL Seqirus to Highlight Commitment to Influenza Protection with More than 20 Data Presentations at OPTIONS XI
Aug 19, 2022 01:00AM Kapruvia® approved in Switzerland with additional regulatory decisions expected in H2 2022
Aug 17, 2022 11:00AM CSL Announces Positive Top-Line Phase 3 Results for Garadacimab as Preventive Treatment in Patients with Hereditary Angioedema (HAE)
Aug 16, 2022 06:45PM CSL announces carbon emissions reduction targets
Aug 10, 2022 10:30AM CSL LAUNCHES NEW UNIFIED GLOBAL BRAND IDENTITY
Aug 4, 2022 03:07PM CSL Plasma Reimagines Donor Experience With First Donations Completed on Innovative Plasma Collection Technology
Jul 11, 2022 08:00AM Seqirus Begins Shipping Portfolio of Innovative Influenza Vaccines for the 2022/23 U.S. Season
Jun 22, 2022 05:30PM CDC Advisory Committee Includes FLUAD® QUADRIVALENT as a Preferentially Recommended Influenza Vaccine for Adults 65 and Older
Jun 9, 2022 08:00AM Acclaimed Photographer Rankin and CSL Behring Team Up to Launch 'Portraits of Progress', an Exhibition Chronicling the Past, Present and Future of Life with Hemophilia
View Older Stories